Il‐Young Kweon

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy

Hyun‐Gyung Goh, Yoo‐Jin Kim, Dong‐Wook Kim et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2009 · 58 citations

Medicine, Hematology, Oncology +16

Analysis of Bcr‐Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P‐loop and T315I mutation is disease phase dependent

Soo‐Hyun Kim, Dong‐Ho Kim, Dong‐Ho Kim et al. · Hematological Oncology · 2009 · 55 citations

Medicine, Genetics, Hematology +9

Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations

Dong‐Ho Kim, Dong‐Wook Kim, Byung‐Sik Cho et al. · Leukemia Research · 2009 · 19 citations

Medicine, Oncology, Pharmacology +15

Dynamic change of T315I BCR‐ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors

Wan‐Seok Kim, Dong‐Ho Kim, Dong‐Ho Kim et al. · Hematological Oncology · 2009 · 11 citations

Medicine, Hematology, Oncology +13